Skip to main content
. 2024 Mar 4;22:239. doi: 10.1186/s12967-024-05035-8

Table 1.

Patient characteristics

Responder, n = 14 Non-responder, n = 21
Sex
 F 5 (36%) 9 (43%)
 M 9 (64%) 12 (57%)
Stage at diagnosis
 I 4 (29%) 8 (38%)
 II 3 (21%) 3 (14%)
 III 5 (36%) 7 (33%)
 IV 2 (14%) 3 (14%)
Histology
 Adenocarcinoma 12 (86%) 12 (57%)
 Squamous Cell Carcinoma 2 (14%) 9 (43%)
IO treatment
 DURVALUMAB 1 (7.1%) 0 (0%)
 NIVOLUMAB 10 (71%) 18 (86%)
 PEMBROLIZUMAB 3 (21%) 3 (14%)
Status
 Alive 13 (93%) 8 (38%)
 Deceased 1 (7.1%) 13 (62%)